PharmCAT.NET

Биостатистика, фармакокинетика и клинические исследования.

  • Домашняя страница
    • О сайте
  • Материалы
    • Быстрые команды R Project
    • Ссылки
  • Инструменты
    • Рандомизационный список
  • Блог
    • Статистика
    • Phoenix WinNonlin
    • IT
    • Путевые заметки
  • Контакты
    • Контактные данные
    • Консультации
    • Конфиденциальность
  • Профиль
    • Войти
    • Зарегистрироваться

Adaptive Designs for Clinical Trials of Drugs and Biologics Guidance for Industry – FDA

Опубликовано 3 октября, 201817 декабря, 2018 frozencat

Обновление руководства FDA:

Adaptive Designs for Clinical Trials of Drugs and Biologics Guidance for Industry

Руководство замещает Adaptive Design Clinical Trials for Drugs and Biologics – 2010.

Рубрики: Блог

Навигация по записям

Предыдущая запись: Определение объема выборки для исследований биоэквивалентности с использованием компьютерного моделирования
Следующая запись: Работа с данными в IBM SPSS: присвоение меток переменным из другого источника

Свежие записи

  • Long WS Wide: или про то, как выполнить анализ разницы изменений между группами
  • Частые вопросы: Регистрация и экспертиза по правилам ЕАЭС
  • Главные ошибки при формировании базы данных в MS Excel
  • Тест ClinicalTrialUtilities и ReplicateBE на Raspberry Pi 4
  • Julia:ReplicateBE – release 0.2.0

Галерея

20170730 125846
20170804 134902
20180131 160131
20180815 184358
20180811 212646
20170729 203919
  • Generic Drug User Fee Amendments
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-07-19 By FDA
  • International Activities
    Source: FDA - What's New: Vaccines, Blood & Biologics RSS Feed Published on 2025-07-19 By FDA
  • GDUFA Implementation Quarterly Meetings between FDA and Industry
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-07-18 By FDA
  • List of Drug Master Files (DMFs)
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-07-18 By FDA
  • Regenerative Medicine Advanced Therapy Designation
    Source: FDA - What's New: Vaccines, Blood & Biologics RSS Feed Published on 2025-07-18 By FDA
  • Human medicines European public assessment report (EPAR): Apremilast Accord, apremilast, Date of authorisation: 19/04/2024, Revision: 1, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-07-18
  • Human medicines European public assessment report (EPAR): Talzenna, talazoparib, Date of authorisation: 20/06/2019, Revision: 10, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-07-18
  • E21 Inclusion of Pregnant and Breastfeeding Women in Clinical Trials
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-07-18 By FDA
  • Human medicines European public assessment report (EPAR): Ztalmy, ganaxolone, Date of authorisation: 26/07/2023, Revision: 5, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-07-18
  • Human medicines European public assessment report (EPAR): Lazcluze, lazertinib, Date of authorisation: 20/01/2025, Revision: 1, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-07-18
  • Human medicines European public assessment report (EPAR): Afqlir, aflibercept, Date of authorisation: 13/11/2024, Revision: 3, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-07-18
  • Human medicines European public assessment report (EPAR): Osenvelt, denosumab, Date of authorisation: 14/02/2025, Revision: 3, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-07-18
  • European Medicines Agency Write PMS API implementation Guide
    Source: EMA - Regulatory and procedural guidelines (human and veterinary) Published on 2025-07-18
  • Human medicines European public assessment report (EPAR): Yesafili, aflibercept, Date of authorisation: 15/09/2023, Revision: 5, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-07-18
  • Human medicines European public assessment report (EPAR): Fampridine Accord, fampridine, Date of authorisation: 24/09/2020, Revision: 5, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-07-18
Предыдущие записи
Тема: Scaffold от Danny Cooper.